NASDAQ
MENS
Last Price
US $2.22
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Jyong Biotech Ltd. Ordinary Shares cash flow to debt ratio of -16.39% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial stability - Healthy cash flow growth.
Jyong Biotech Ltd. Ordinary Shares's free cash flow has increased -16.09% from $-3.62M last year to $-3.04M, signaling increasing performance
Financial risk - Healthy debt to equity ratio.
Jyong Biotech Ltd. Ordinary Shares's debt to equity ratio is -0.74, signaling that the company spent its equity and risk bankruptcy.
Financial risk - Healthy debt to equity ratio development.
Jyong Biotech Ltd. Ordinary Shares's debt to equity ratio is -0.74, signaling that the company spent its equity and risk bankruptcy.
Financial risk - Net debt/EBITDA.
Jyong Biotech Ltd. Ordinary Shares has negative EBITDA, making leverage ratio unreliable
Financial risk - ICR.
Jyong Biotech Ltd. Ordinary Shares's interest coverage ratio is -1.03, which means that the company struggles to meet interest obligations, signaling financial risk.
Financial risk - Profit margin growth.
Jyong Biotech Ltd. Ordinary Shares has insufficient data to evaluate this check.
Financial risk - Short term assets vs short term liabilities.
Jyong Biotech Ltd. Ordinary Shares's short-term liabilities of $34.81M exceed its short-term assets of $15.54M, signaling financial risk
Decreasing performance - ROA.
Jyong Biotech Ltd. Ordinary Shares's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Increasing performance - Absolute return on equity.
Jyong Biotech Ltd. Ordinary Shares's return on equity of 19.72%, is higher than 15.00%, indicating good performance
Decreasing performance - Earnings quality.
Jyong Biotech Ltd. Ordinary Shares's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Jyong Biotech Ltd. Ordinary Shares had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Jyong Biotech Ltd. Ordinary Shares has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Jyong Biotech Ltd. Ordinary Shares has negative free cash flow, indicating cash burn
Decreasing performance - Healthy earnings growth.
Jyong Biotech Ltd. Ordinary Shares's yearly earnings has decreased 54.72% since last year from $-3.02M to $-4.67M, signaling decreasing performance
Increasing performance - Healthy revenue growth.
Jyong Biotech Ltd. Ordinary Shares's yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance
Increasing performance - ROIC.
ROIC 45.99% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.
Decreasing performance - 3-year revenue CAGR.
Jyong Biotech Ltd. Ordinary Shares has insufficient revenue history to calculate 3-year revenue CAGR.
Increasing performance - Revenue consistency.
Jyong Biotech Ltd. Ordinary Shares had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
Jyong Biotech Ltd. Ordinary Shares had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Jyong Biotech Ltd. Ordinary Shares has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Jyong Biotech Ltd. Ordinary Shares has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Jyong Biotech Ltd. Ordinary Shares is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Jyong Biotech Ltd. Ordinary Shares has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
Jyong Biotech Ltd. Ordinary Shares has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - P/B ratio.
Jyong Biotech Ltd. Ordinary Shares has negative shareholder equity; price-to-book is not meaningful and the check fails
Overvalued - P/S ratio.
Jyong Biotech Ltd. Ordinary Shares has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
19.72%
Return on equity
ROIC: 45.99%
Valuation History
-29.6X
Price to Earnings
EV/EBITDA: -61.0X
Cash flow
Profit margin
-
(FY vs FY)
Cash flow Y/Y
-
(FY vs FY)
Fair Value
Market $2.22
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.